Levi & Korsinsky LLP
09/20/2025 | Press release | Distributed by Public on 09/20/2025 07:41
Investors Blindsided By RXST Losses Lawsuit Follows
RxSight boasted about booming demand for its cataract surgery system. But, in the end, the company took the scalpel to investors wallets. After investors got blindsided by plummeting demand and a slashed revenue guidance, shareholders dumped their stock. RxSight's stock price crashed by almost 40%. Now, investors are suing.
RxSight manufacturers a surgical kit which it says helps people with cataracts. From late 2024 to early 2025, RxSight kept up a story of surging demand and great revenue. In early 2025 it even issued an eye-popping revenue guidance. But it was all smoke, no substance.
Investors learned the truth in July after the company admitted demand was crashing out. The Company slashed its revenue guidance. Furious investors dumped their shares, sending the stock into freefall.
Now, more investors are joining the lawsuit.
Levi & Korsinsky LLP published this content on September 20, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 20, 2025 at 13:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]